Blue Door Pharma and Global Energy Markets Strike Global Export Agreement for Meningitis Vaccine and Pharmaceuticals

Blue Door Pharma and Global Energy Markets reach an agreement to export pharmaceuticals, including a low cost, animal-free meningitis vaccine, to customers world-wide.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
It is a strong marriage of skills, expertise and regulatory licensing on both sides of the equation.

Rockville, MD (PRWEB) January 11, 2013

Blue Door Pharmacies, LLC (T/A Blue Door Pharma) announces it has executed a five year, exclusive joint partnership with Global Energy Markets, LLC for the sale and global distribution of pharmaceuticals and a low cost tetravalent meningitis vaccine. Operating under the joint partnership name BlueGem Global, the companies are in negotiations with organizations in Algeria, the Dominican Republic, Ghana, Indonesia and Iran.

“Global Energy Markets needed Blue Door Pharma’s expertise, and they needed ours,” said Global Energy Markets President and CEO, Sina Soumekhian, “For years our clients have asked for pharmaceutical access, and with this partnership we can provide it. Plus, we believe the low cost meningitis vaccine we provide will prove to be highly desirable in our target markets.”

Global Energy Markets has a broad network of international contacts and a license issued by the U.S. Department of Treasury, Office of Foreign Assets Control (OFAC), allowing them to export items to countries under US sanction. “It is a strong marriage of skills, expertise and regulatory licensing on both sides of the equation,” said Dr. Sheila Alizadeh, Founder and CEO of Blue Door Pharma.


Contact